Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alkeus Pharmaceuticals Inc. has a very focused prosecution profile with only 1 pending office action. This single matter is located within the Biotechnology & Pharmaceuticals technology area. KEVIN STEPHEN MARTIN is the sole examiner assigned to this case, which is situated in 1 distinct art unit. With only 1 pending office action and 1 distinct examiner, the company's current patent office activity is highly centralized.
The reliance on a single official, KEVIN STEPHEN MARTIN, means that the company's immediate success in the Biotechnology & Pharmaceuticals sector depends on one person's interpretation. Because there is only one pending matter, there are no other cases to provide a baseline for comparison within the 1 distinct art unit. This prosecution strategy is entirely dependent on the specific requirements of 1 distinct examiner. The company must ensure its arguments are perfectly tailored to the standards of this single official to secure its intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, KEVIN STEPHEN | 1 | 77.4% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19656478 | TREATMENT FOR ASYMPTOMATIC STARGARDT DISEASE PATIENTS | MARTIN, KEVIN STEPHEN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19656478 | TREATMENT FOR ASYMPTOMATIC STARGARDT DISEASE PATIENTS | MARTIN, KEVIN STEPHEN | 1624 | §103DP | Non-Final OA | — | Pending | Apr 23, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlkeus Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kevin Stephen Martin has the most, with 1 of Alkeus Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
